ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
JUN | Jun proto-oncogene | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK9 | Potassium channel, subfamily K, member 9 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
KEAP1 | Kelch-like ECH-associated protein 1 | Cancer-related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP4 | Microtubule-associated protein 4 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
METAP2 | Methionyl aminopeptidase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
MPL | MPL proto-oncogene, thrombopoietin receptor | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
MTR | 5-methyltetrahydrofolate-homocysteine methyltransferase | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins Transcription factors
| | | | | Expressed in all |
NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PDXK | Pyridoxal (pyridoxine, vitamin B6) kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
PLAUR | Plasminogen activator, urokinase receptor | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PLIN3 | Perilipin 3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
POLA1 | Polymerase (DNA directed), alpha 1, catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
POLE | Polymerase (DNA directed), epsilon, catalytic subunit | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
POLE2 | Polymerase (DNA directed), epsilon 2, accessory subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
PPARG | Peroxisome proliferator-activated receptor gamma | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRKAA1 | Protein kinase, AMP-activated, alpha 1 catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PRKAB1 | Protein kinase, AMP-activated, beta 1 non-catalytic subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB10 | Proteasome (prosome, macropain) subunit, beta type, 10 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB2 | Proteasome (prosome, macropain) subunit, beta type, 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB5 | Proteasome (prosome, macropain) subunit, beta type, 5 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB9 | Proteasome (prosome, macropain) subunit, beta type, 9 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RARA | Retinoic acid receptor, alpha | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transcription factors
| | | | | Expressed in all |
RARB | Retinoic acid receptor, beta | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Mixed |
RARG | Retinoic acid receptor, gamma | Cancer-related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
RET | Ret proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
RPL3 | Ribosomal protein L3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins Ribosomal proteins
| | | | | Expressed in all |
RRM1 | Ribonucleotide reductase M1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
RRM2 | Ribonucleotide reductase M2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
RXRA | Retinoid X receptor, alpha | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
RXRB | Retinoid X receptor, beta | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
SCNN1D | Sodium channel, non-voltage-gated 1, delta subunit | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SHMT1 | Serine hydroxymethyltransferase 1 (soluble) | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |